Jason E Farrar, MD

Research Program: Cancer Biology Faculty Rank: Associate Professor Campus: Arkansas Children's Hospital College: College of Medicine Department: Pediatrics

Cancer Research Interest

• Disease Site Focus: Pediatric Oncology, Hematologic Malignancies
• Research Focus Area: Treatment, Informatics, Detection, Diagnosis/ Prognosis
• Type of Research: Clinical, Translational
• Research Interest Statement: I am a pediatric hematologist/oncologist with clinical interests in childhood leukemia, lymphomas and cancer-prone disorders such as inherited bone marrow failure and myelodysplastic syndromes. Our research program focuses on understanding the genetic basis of abnormal bone marrow function that underlies these diseases in children in order to identify new therapeutic options and improve treatment outcomes.

Contact Information

• Email Address: JEFARRAR@UAMS.EDU
• Profiles Research Networking Software: View Profile

Recent Publications

• Doan DT, Strebeck PV, Tran AD, [et al., including Farrar JE]. Evaluation of recurrent and recalcitrant warts in a deaf adolescent male reveals GATA2 deficiency. The journal of allergy and clinical immunology. Global. 2024 3(4):100313. PMID: 39221430. PMCID: PMC11364118.
• Wlodarski MW, Vlachos A, Farrar JE, [et al.]. Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement. The Lancet. Haematology. 2024 11(5):e368-e382. PMID: 38697731.
• Appell LE, Mack JM, Farrar JE, [et al.]. Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease. Pediatrics. 2024 153(4). PMID: 38511235.
• Abla O, Ries RE, Triche TJ Jr, [et al., including Farrar JE]. Structural variants involving MLLT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia. Blood advances. 2024. PMID: 38306602. PMCID: PMC11024924.
• Frett B, Stephens KE, Koss B, [et al., including Farrar J]. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia. Cancer science. 2024. PMID: 38226414. PMCID: PMC10920984.
• Sun JM, Chow WY, Xu G, [et al., including Farrar JE]. The Role of FAS Receptor Methylation in Osteosarcoma Metastasis. International journal of molecular sciences. 2023 24(15). PMID: 37569529. PMCID: PMC10418590.
• Farrar JE, Othus M, Wang YC, [et al.]. Reply to Z.R. McCaw et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2300986. PMID: 37390387. PMCID: PMC10522099.
• Bertrums EJM, Smith JL, Harmon L, [et al., including Farrar JE]. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023. PMID: 36815378. PMCID: PMC10388277.
• Farrar JE, Smith JL, Othus M, [et al.]. Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2201114. PMID: 36795987. PMCID: PMC10414715.
• Huang BJ, Smith JL, Farrar JE, [et al.]. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nature communications. 2022 13(1):5487. PMID: 36123353. PMCID: PMC9485122.
• Hu Y, Caldwell KJ, Onciu M, [et al., including Farrar JE]. CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood advances. 2021. PMID: 34710216. PMCID: PMC8791570.
• Huang BJ, Smith J, Wang J, [et al., including Farrar JE]. CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes. Blood advances. 2021. PMID: 34547772. PMCID: PMC9153007.
• Gill PS, Yu FB, Porter-Gill PA, [et al., including Farrar JE]. Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children's Hospital. Journal of personalized medicine. 2021 11(5). PMID: 34064668. PMCID: PMC8150685.
• Douglass DP, Stine KC, Farrar JE. A Novel Germline TP53 Mutation in a Patient With Li-Fraumeni Syndrome: Resolving a Variant of Uncertain Significance. Journal of pediatric hematology/oncology. 2021. PMID: 33633026.
• Li J, Galbo PM Jr, Gong W, [et al., including Farrar JE]. ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism. Nature communications. 2021 12(1):1045. PMID: 33594072. PMCID: PMC7886901.
• Bolouri H, Ries R, Pardo L, [et al., including Farrar JE]. A B-cell developmental gene regulatory network is activated in infant AML. PloS one. 2021 16(11):e0259197. PMID: 34793513. PMCID: PMC8601427.
• Hecht A, Meyer JA, Behnert A, [et al., including Farrar JE]. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia. Haematologica. 2020 Online ahead of print. PMID: 33375775. PMCID: PMC8719097.
• Vlachos A, Atsidaftos E, Lababidi ML, [et al., including Farrar JE]. L-leucine improves anemia and growth in patients with transfusion-dependent Diamond-Blackfan anemia: Results from a multicenter pilot phase I/II study from the Diamond-Blackfan Anemia Registry. Pediatric blood & cancer. 2020:e28748. PMID: 33025707. PMCID: PMC8273758.
• Gianferante DM, Wlodarski MW, Atsidaftos E, [et al., including Farrar JE]. Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A. Haematologica. 2020. PMID: 32241839. PMCID: PMC8094096.
• Smith JL, Ries RE, Hylkema T, [et al., including Farrar JE]. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 26(3):726-737. PMID: 31719049. PMCID: PMC7002196.